ASH News Daily 2012 - Tuesday, December 11, 2012 - (Page A-1)

ASH NEWS DAILY 54th Annual Meeting of the American Society of Hematology ® Read this issue online at SCHEDULE Registration 7:00 a.m. – 1:00 p.m. Hall A2, Level 1, Building A 7:15 – 9:15 a.m. Special Symposium on the Basic Science of Hemostasis and Thrombosis (invited presentations) Georgia Ballroom 3, Level 3, Building C 7:30 – 9:00 a.m. Simultaneous Oral Sessions Various locations in GWCC 7:30 – 9:00 a.m. Late-Breaking Abstracts Session Hall B5, Level 1, Building B 9:30 – 9:45 a.m. Announcement of the Dameshek Prize and the Stratton Medal Hall B5, Level 1, Building B 9:45 – 11:15 a.m. Presidential Symposium Hall B5, Level 1, Building B 11:15 – 11:30 a.m. Business Meeting Hall B5, Level 1, Building B 12:00 noon – 1:00 p.m. Best of ASH Sidney Marcus Auditorium, Level 4, Building A Hope I Die Before I Get Old (Talkin’ About My Regeneration) them is that Dr. Keating has been far subtler in moving the field forward (I don’t recall anyone observing Dr. Keating windmilling a stethoscope, but maybe I’m wrong). Continuing his vision, Dr. Keating will chair the Presidential BY MICHAEL R. BISHOP, MD in many ways he and Pete Townshend (for those of you who don’t know, I IN THIS SECTION Stratton and Dameshek A-3 Thrombosis A-4 Stem Cells A-5 Sequencing in MDS A-7 Pete’s the musician who wrote the song “My Generation”) share many characteristics in that they are both visionaries, they continue to be interested in new ideas, and both have influenced numerous peers. The major difference between ’m not sure whether ASH President Armand Keating, MD, will appreciate the comparison, but Symposium entitled “Regenerative Medicine” starting at 9:45 a.m. this morning in Hall B5, Level 1, Building B. Regenerative medicine has long been an interest of Dr. Keating’s, »»REGENERATION Page A-6 Dr. Timothy J. Ley opens his E. Donnall Thomas Lecture by paying tribute to Thomas, who passed away this year. See page A-2 for a recap of Dr. Ley’s presentation. Effective Efficacy BY MARC J KAHN, MD, MBA he difference between efficacy and effectiveness in a clinical trial is how the efficacy of the trial translates in effectiveness when the intervention is applied to real populations of real patients. Health services research deals with how patients get access to practitioners, medications, and services and what happens to them as a result of this care. Health services research blends the social factors of care with the scientific factors of clinical research. Issues of cost, availability, access, social acceptance and personal behaviors all affect the effectiveness of an efficacious intervention. Health services research goes beyond the clinical laboratory and into the home and community. Yesterday, several Oral sessions pertaining to health services research for issues in the non-malignant hematology arena were presented. The results of the presented abstracts were at times surprising and may lead to changes in practice. Jessica A. Reese, MS, from the University of Oklahoma, T pre- ASH News Daily author Jose Bufill, MD, sat down with the new editors of Blood, Dr. Bob Löwenberg and Dr. Nancy Berliner. Turn to page A-6 to read the conversation. sented abstract 362 detailing morbidity and mortality following recovery from an acute episode of thrombotic thrombocytopenic purpura (TTP). Although recovery from an episode of acute TTP is typically assumed to be complete, the authors of this study showed a lower life expectancy for survivors of TTP and further demonstrated that hypertension and diabetes are both previously unrecognized risk factors for poor health outcomes in this population. Another study using the same database, presented by Cassandra C. Deford, MA, also from the University of Oklahoma, »»EFFICACY Page A-2

Table of Contents for the Digital Edition of ASH News Daily 2012 - Tuesday, December 11, 2012

ASH News Daily 2012 - Tuesday, December 11, 2012